Status: Ongoing
First registered on:
07/06/2018
Last updated on:
20/12/2019
1. Study identification
EU PAS Register NumberEUPAS24364
Official titleMonitoring prEscription druG Abuse using DOctor Shopping bEhavior
Study title acronymMEGADOSE
Study typeObservational study
Brief description of the studyPrescription drug abuse is a major challenge in public health, in particular in countries such as France, one of the main consumers of medication in Europe. A single source of information is rarely sufficient to measure such a complex phenomenon. This project entitled MEGADOSE (Monitoring prEscriptiondruG Abuse using DOctor Shopping bEhavior) may complete efficiently the available data from the addictovigilance centres allowing the health authorities (French Drug Agency) to answer to the main general questions (What are the main prescription drug abused in France? What are the national trends in prescription drug abuse? What is the impact of a public health measure on prescription drug abuse).
The general aim of this project is to provide an up-to-date and nationally consolidated estimation of the risk and the extent of abuse associated with more of 100 psychoactive drugs in the French population, using doctor-shopping method on National SNIIR-AM.
The primary objective of this study is to assess medication availability and the extent and risk of abuse of all psychoactive reimbursed drugs at a national level according to the doctor shopping method.
All psychoactive drugs will be ranked according to their DSQ (used as a proxy of the extent of abuse) and their DSI (used as a proxy of abuse potential).
Three levels of analysis will be performed: analysis at the class, medications and formulation level (dosage, route of administration, extended or immediate release).
The secondary objectives include:
i) a geographic approach (spatial analysis) in order to assess differences of psychotropic drugs exposure and abuse between areas and to highlight the detection of an emerging signal in specific areas;
ii) a dynamic approach (temporal analysis) to assess the evolution of abuse and the impact of measures between 2010 and, 2015 and 2016.
Was this study requested by a regulator?No
Is the study required by a Risk Management Plan (RMP)?
Not applicable
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicable
2. Research centres and Investigator details
Coordinating study entity
Centre to which the investigator belongsUPCET
Department/Research groupPharmacology Department
Organisation/affiliationUPCET
Details of (Primary) lead investigator
Title Dr
Last name MICALLEF
First name Joelle
Is this study being carried out with the collaboration of a research network?
No
Other centres where this study is being conducted
Multiple centres
In total how many centres are involved in this Study?2
Countries in which this study is being conducted
National study
France
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed05/12/2016
Start date of data collection01/01/2010
Start date of data analysis
Date of interim report, if expected
Date of final study report31/12/2020
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companies
Charities
Government bodyAgence nationale de sécurité du médicament et des produits de santé61
Research councils
EU funding scheme
OtherAssistance publique – Hôpitaux de Marseille39
5. Contact details for enquiries
Scientific Enquiries
Title Professor
Last name Micallef
First name Joëlle
Address line 1Assistance publique – Hôpitaux de Marseille
Address line 2Service de pharmacologie clinique
Address line 3264 Rue Saint Pierre
CityMarseille
Postcode13005
CountryFrance
Phone number (incl. country code)33491387563
Alternative phone number
Fax number (incl. country code)
Public Enquiries
Title Professor
Last name Micallef
First name Joëlle
Address line 1Assistance publique – Hôpitaux de Marseille
Address line 2Service de pharmacologie clinique
Address line 3264 Rue Saint Pierre
CityMarseille
Postcode13005
CountryFrance
Phone number (incl. country code)33491387563
Alternative phone number
Fax number (incl. country code)
6. Study drug(s) information
Substance class (ATC Code)N (NERVOUS SYSTEM)
Substance class (ATC Code)M03B (MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS)
Substance class (ATC Code)R05 (EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS)
Substance class (ATC Code)R06 (ANTIHISTAMINES FOR SYSTEMIC USE)
7. Medical conditions to be studied
Medical condition(s)No
8. Population under study
Age
Adults (18 - 44 years)
Adults (45 - 64 years)
Adults (65 - 74 years)
Adults (75 years and over)
Sex
Male
Female
9. Number of subjects
Estimated total number of subjects50000000
10. Source of data
Is this study being carried out with an established data source?Yes
Data sources not registered with ENCePP
SNIIRAM, France
Sources of data
Administrative database, e.g. claims database
11. Scope of the study
What is the scope of the study?
Risk assessment
Drug utilisation study
Primary scope : Drug utilisation study
12. Main objective(s)
What is the main objective of the study?
The primary objective of this study is to assess medication availability and the extent and risk of abuse of all psychoactive reimbursed drugs at a national level according to the doctor shopping method.
Are there primary outcomes?Yes
Doctor Shopping parameters
The principle of calculation is based on the number of overlaps of prescriptions of a given medication (or class of medication) from different prescribers for a given patient.
Are there secondary outcomes?No
13. Study design
What is the design of the study?
Cohort study
Drug utilisation study
14. Follow-up of patients
Will patients be followed up?Yes
Please describe duration of follow up
According to the SNIIRAM data
15. Data analysis plan
Please provide a brief summary of the analysis method
For the first objective we will perform three levels of analysis. First, classes will be ranked according to the doctor shopping parameters. For this level we will analyze the classes for which all medications were included. Then, the medications will be ranked according to doctor shopping. Finally, we will compare the different formulations available for medications with a DSI superior to 1% (according to dosage, route of administration, extended or immediate release).
For the second objectives we will describe the volume of reimbursement, DSQc and DSI in each area for each classes and medication. We will apply all these analyses during each year selected in order to assess the evolution of abuse and the impact of different measures.
16. ENCePP seal
Are you requesting the ENCePP seal for this study?
No
17. Full protocol
Not submitted
18. Study Results
Not submitted
Please list the 5 most relevant publications using data from your study
ReferenceLink to web-publication
None
19. Other relevant documents
Conflict(s) of interest of
investigator(s)Not submitted
Composition of Steering Group and
ObserversNot submitted
Other documentsNot
submitted
Signed Code of
Conduct Checklist
Not submitted
Signed Code of Conduct Declaration
Not submitted
Signed Checklist for Study
Protocols
Not submitted
